Stay updated on Rilzabrutinib for CSU: H1 Resistant - Clinical Trial
Sign up to get notified when there's something new on the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page.

Latest updates to the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page
- Check6 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA 403 Forbidden error page appears when attempting to view the study record, showing a 403 message. A Home button is present, indicating restricted access rather than the study content.SummaryDifference17%

- Check27 days agoChange DetectedThe page's revision label has updated from v3.6.6 to v3.7.0, indicating a newer release of the page template/system without altering study content.SummaryDifference0.0%

- Check41 days agoChange DetectedA new revision line 'Revision: v3.6.6' was added and the previous 'Revision: v3.6.5' was removed, updating the page's revision history.SummaryDifference0.0%

- Check62 days agoChange DetectedOn 2026-08-06, the study record adds a Results Posted entry and updates the open-label extension to allow either dose B or dose C with specified follow-up weeks. Enrollment is listed as 160, and several secondary outcomes and eligibility details have been revised to reflect the new design and reporting status.SummaryDifference1%

- Check83 days agoChange DetectedResults status on the study page now shows 'Results Submitted,' replacing the previous 'No Results Posted.' The page revision has been updated to v3.6.4 from v3.6.3.SummaryDifference0.0%

Stay in the know with updates to Rilzabrutinib for CSU: H1 Resistant - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rilzabrutinib for CSU: H1 Resistant - Clinical Trial page.